The Tmod cellular logic gate as a solution for tumor-selective immunotherapy.
|Title:||The Tmod cellular logic gate as a solution for tumor-selective immunotherapy.|
|Authors:||DiAndreth B; A2 Biotherapeutics, 30301 Agoura Rd., Agoura Hills, CA 91301, USA. Electronic address: firstname.lastname@example.org., Hamburger AE; A2 Biotherapeutics, 30301 Agoura Rd., Agoura Hills, CA 91301, USA., Xu H; A2 Biotherapeutics, 30301 Agoura Rd., Agoura Hills, CA 91301, USA., Kamb A; A2 Biotherapeutics, 30301 Agoura Rd., Agoura Hills, CA 91301, USA. Electronic address: email@example.com.|
|Source:||Clinical immunology (Orlando, Fla.) [Clin Immunol] 2022 Aug; Vol. 241, pp. 109030. Date of Electronic Publication: 2022 May 11.|
|Publication Type:||Journal Article; Review|
|Journal Info:||Publisher: Academic Press Country of Publication: United States NLM ID: 100883537 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-7035 (Electronic) Linking ISSN: 15216616 NLM ISO Abbreviation: Clin Immunol Subsets: MEDLINE|
|Imprint Name(s):||Original Publication: Orlando, FL : Academic Press, c1999-|
|MeSH Terms:||Immunotherapy* , Neoplasms*/therapy, Humans ; Immunotherapy, Adoptive|
|Abstract:||Immune cells that are engineered with receptors to integrate signals from multiple antigens offer a promising route to achieve the elusive property of therapeutic selectivity in cancer patients. Several types of multi-signal integrators have been described, among them mechanisms that pair activating and inhibitory receptors which are termed NOT gates by analogy to logical operations performed by machines. Here we review one such NOT-gated signal integrator called the Tmod system which is being developed for patients with solid tumors. Coupled with rigorous selection for patients with defined lesions in their tumor genomes (loss of heterozygosity), the Tmod approach presents an unusual opportunity to create truly selective therapies for certain cancer patients. Several of these agents are advancing toward the clinic, supported by a large body of quantitative preclinical data.
(Copyright © 2022 A2 Biotherapeutics, Inc. Published by Elsevier Inc. All rights reserved.)
|Contributed Indexing:||Keywords: CAR-T; LILRB1; LIR-1; Logic gate; NOT gate; Synthetic biology; T cell therapy|
|Entry Date(s):||Date Created: 20220513 Date Completed: 20220809 Latest Revision: 20220825|